CN1517094A - 单唾液酸四已糖神经节苷脂脂质体复合物制剂 - Google Patents
单唾液酸四已糖神经节苷脂脂质体复合物制剂 Download PDFInfo
- Publication number
- CN1517094A CN1517094A CNA031011543A CN03101154A CN1517094A CN 1517094 A CN1517094 A CN 1517094A CN A031011543 A CNA031011543 A CN A031011543A CN 03101154 A CN03101154 A CN 03101154A CN 1517094 A CN1517094 A CN 1517094A
- Authority
- CN
- China
- Prior art keywords
- monostalotetrahexosylgangliside
- liposome
- phospholipid
- liposome complex
- ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 70
- 238000002360 preparation method Methods 0.000 title claims description 22
- 239000002253 acid Substances 0.000 title abstract description 3
- 150000002270 gangliosides Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 claims abstract description 19
- 230000001154 acute effect Effects 0.000 claims abstract description 3
- 230000001684 chronic effect Effects 0.000 claims abstract 2
- 150000003904 phospholipids Chemical class 0.000 claims description 20
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 229940042880 natural phospholipid Drugs 0.000 claims description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- 102000002322 Egg Proteins Human genes 0.000 claims description 2
- 108010000912 Egg Proteins Proteins 0.000 claims description 2
- 241000287828 Gallus gallus Species 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 210000004681 ovum Anatomy 0.000 claims description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 229940083466 soybean lecithin Drugs 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 1
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 125000005314 unsaturated fatty acid group Chemical group 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 4
- 208000028389 Nerve injury Diseases 0.000 abstract description 2
- 230000008764 nerve damage Effects 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 230000006872 improvement Effects 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 8
- 230000002490 cerebral effect Effects 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000010408 film Substances 0.000 description 6
- 239000010409 thin film Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 101001000212 Rattus norvegicus Decorin Proteins 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- FVJZSBGHRPJMMA-UHFFFAOYSA-N distearoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000703 high-speed centrifugation Methods 0.000 description 3
- 238000003475 lamination Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000003223 protective agent Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 208000001738 Nervous System Trauma Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 208000028412 nervous system injury Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- KLFKZIQAIPDJCW-GPOMZPHUSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-GPOMZPHUSA-N 0.000 description 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 241000459479 Capsula Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 244000287680 Garcinia dulcis Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- JCABVIFDXFFRMT-DIPNUNPCSA-N [(2r)-1-[ethoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] octadec-9-enoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC)OC(=O)CCCCCCCC=CCCCCCCCC JCABVIFDXFFRMT-DIPNUNPCSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (17)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031011543A CN100348198C (zh) | 2003-01-13 | 2003-01-13 | 单唾液酸四已糖神经节苷脂脂质体复合物制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031011543A CN100348198C (zh) | 2003-01-13 | 2003-01-13 | 单唾液酸四已糖神经节苷脂脂质体复合物制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1517094A true CN1517094A (zh) | 2004-08-04 |
CN100348198C CN100348198C (zh) | 2007-11-14 |
Family
ID=34281362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031011543A Expired - Fee Related CN100348198C (zh) | 2003-01-13 | 2003-01-13 | 单唾液酸四已糖神经节苷脂脂质体复合物制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100348198C (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100411610C (zh) * | 2005-12-29 | 2008-08-20 | 武汉海特生物制药股份有限公司 | 一种可透血脑屏障的脂质体和以该脂质体为载体的药物组合物及其制备方法 |
CN101700230B (zh) * | 2009-11-06 | 2012-02-01 | 山东大学 | 一种单唾液酸四己糖神经节苷酯微球及其制备方法 |
CN102366408A (zh) * | 2011-09-14 | 2012-03-07 | 海南灵康制药有限公司 | 单唾液酸四己糖神经节苷脂钠脂质体注射剂 |
CN102988284A (zh) * | 2012-12-13 | 2013-03-27 | 哈药集团技术中心 | 一种单唾液酸四己糖神经节苷脂钠注射液的制备方法 |
CN106361718A (zh) * | 2016-10-14 | 2017-02-01 | 珠海赛隆药业股份有限公司 | 单唾液酸四己糖神经节苷脂钠的结肠靶向生物粘附片 |
CN106619545A (zh) * | 2016-10-14 | 2017-05-10 | 珠海赛隆药业股份有限公司 | 在胃肠道稳定的单唾液酸四己糖神经节苷脂钠口服制剂及制备方法 |
CN108404139A (zh) * | 2018-01-29 | 2018-08-17 | 南昌大学 | 低浓度单唾液酸四己糖神经节苷脂修饰的重组脂蛋白的制备方法及其应用 |
CN110755405A (zh) * | 2019-10-25 | 2020-02-07 | 南昌大学 | 具有靶向性的神经节苷脂gm3在制备治疗动脉粥样硬化疾病药物中的应用 |
CN113304276A (zh) * | 2021-06-04 | 2021-08-27 | 沈阳药科大学 | 用单唾液酸四己糖神经节苷脂修饰的脂质体及其制法和冻干应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
CN1225815A (zh) * | 1998-06-10 | 1999-08-18 | 南方医院 | 干燥脂质体及其制备方法 |
-
2003
- 2003-01-13 CN CNB031011543A patent/CN100348198C/zh not_active Expired - Fee Related
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100411610C (zh) * | 2005-12-29 | 2008-08-20 | 武汉海特生物制药股份有限公司 | 一种可透血脑屏障的脂质体和以该脂质体为载体的药物组合物及其制备方法 |
CN101700230B (zh) * | 2009-11-06 | 2012-02-01 | 山东大学 | 一种单唾液酸四己糖神经节苷酯微球及其制备方法 |
CN102366408A (zh) * | 2011-09-14 | 2012-03-07 | 海南灵康制药有限公司 | 单唾液酸四己糖神经节苷脂钠脂质体注射剂 |
CN102988284A (zh) * | 2012-12-13 | 2013-03-27 | 哈药集团技术中心 | 一种单唾液酸四己糖神经节苷脂钠注射液的制备方法 |
CN102988284B (zh) * | 2012-12-13 | 2014-04-02 | 哈药集团技术中心 | 一种单唾液酸四己糖神经节苷脂钠注射液的制备方法 |
CN106361718A (zh) * | 2016-10-14 | 2017-02-01 | 珠海赛隆药业股份有限公司 | 单唾液酸四己糖神经节苷脂钠的结肠靶向生物粘附片 |
CN106619545A (zh) * | 2016-10-14 | 2017-05-10 | 珠海赛隆药业股份有限公司 | 在胃肠道稳定的单唾液酸四己糖神经节苷脂钠口服制剂及制备方法 |
CN106361718B (zh) * | 2016-10-14 | 2019-01-25 | 珠海赛隆药业股份有限公司 | 单唾液酸四己糖神经节苷脂钠的结肠靶向生物粘附片 |
CN108404139A (zh) * | 2018-01-29 | 2018-08-17 | 南昌大学 | 低浓度单唾液酸四己糖神经节苷脂修饰的重组脂蛋白的制备方法及其应用 |
CN110755405A (zh) * | 2019-10-25 | 2020-02-07 | 南昌大学 | 具有靶向性的神经节苷脂gm3在制备治疗动脉粥样硬化疾病药物中的应用 |
CN113304276A (zh) * | 2021-06-04 | 2021-08-27 | 沈阳药科大学 | 用单唾液酸四己糖神经节苷脂修饰的脂质体及其制法和冻干应用 |
Also Published As
Publication number | Publication date |
---|---|
CN100348198C (zh) | 2007-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0260811B1 (en) | Phospholipid particles encapsulating polyene antibiotics for the treatment of systemic fungal infections | |
KR970007187B1 (ko) | 개선된 암포테리신 b 리포좀 제조법 | |
RU2734236C2 (ru) | Композиции бендамустина и циклополисахарида | |
EP0380584B1 (en) | Polyene macrolide pre-liposomal powders | |
RU2391966C1 (ru) | Наносистема на основе растительных фосфолипидов для включения биологически активных соединений и способ ее получения (варианты) | |
CN1840193A (zh) | 聚乙二醇衍生化磷脂包载的蒽环类抗肿瘤抗生素的纳米胶束制剂 | |
CN116270473B (zh) | 一种共载脂质体及其制备方法 | |
TW202033183A (zh) | 含有治療失智症之治療劑的緩釋藥物組合物及其用途 | |
CN100348198C (zh) | 单唾液酸四已糖神经节苷脂脂质体复合物制剂 | |
WO2008080369A1 (fr) | Composition liposomale stable | |
DE60025494T2 (de) | Epothilon zusammensetzungen | |
CN1827096A (zh) | 含壳聚糖衍生物的多西他塞脂质体、冻干制剂及制备方法 | |
CN110464835B (zh) | 一种胰岛素柔性微粒及其制剂 | |
CN109498733B (zh) | 一种龙血竭纳米混悬剂及其制备方法 | |
CN101028250A (zh) | 藤黄酸脂质体及其冻干粉针剂与制备方法 | |
TW202021574A (zh) | 含有抗精神病藥物的緩釋藥物組合物及其用途 | |
CN1256949C (zh) | 三七总皂苷脂质体及其制备方法 | |
US5043107A (en) | Preparation small unilamellar vesicles including polyene antifungal antibiotics | |
CN1843368A (zh) | 一种灯盏花素长循环纳米脂质体及其制备方法 | |
CN104173288B (zh) | 一种克拉霉素离子对脂质体注射液及其制备方法 | |
CN104546718B (zh) | 一种长循环雷贝拉唑脂质体组合物及其制备方法和应用 | |
CN1650864A (zh) | 10-羟基喜树碱长循环脂质体及其冻干制剂 | |
US20040175417A1 (en) | Amphotericin B liposome preparation | |
CN110960491A (zh) | 一种负载丹参酮ⅡA的水溶性壳聚糖/γ-聚谷氨酸纳米复合物的制备方法及应用 | |
CN104771362B (zh) | 一种克拉霉素离子对脂质微球注射液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Hainan Sihuan Pharmaceutical Co.,Ltd Assignor: Fujin Bio-Medicine Co., Ltd., Chongqing Contract fulfillment period: 2008.10.7 to 2023.1.13 Contract record no.: 2008460000007 Denomination of invention: Monosialic acid tetrahexose ganglioside liposome complex preparation Granted publication date: 20071114 License type: Exclusive license Record date: 20081024 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.10.7 TO 2023.1.13; CHANGE OF CONTRACT Name of requester: HAINAN SIHUAN PHARMACEUTICAL CO., LTD. Effective date: 20081024 |
|
ASS | Succession or assignment of patent right |
Owner name: HAINAN YI'ER PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: FUJIN BIO-MEDICINE CO LTD, CHONGQING Effective date: 20110928 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 400041 JIULONGPO, CHONGQING TO: 570208 HAIKOU, HAINAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110928 Address after: 570208 Hainan, Haikou Meilan District, Lingshan town Shunda Road, No. 12 Patentee after: Hainan Yi'er Pharmaceutical Co. Ltd. Address before: 400041 No. four, 70 street, Ke garden, Chongqing hi tech Zone Patentee before: Fujin Bio-Medicine Co., Ltd., Chongqing |
|
TR01 | Transfer of patent right |
Effective date of registration: 20170327 Address after: 571126, Shunda Road, Lingshan Town, Meilan District, Hainan, China, 12-2 Patentee after: Hainan Yi'er Biological Pharmaceutical Co Ltd Address before: 570208 Hainan, Haikou Meilan District, Lingshan town Shunda Road, No. 12 Patentee before: Hainan Yi'er Pharmaceutical Co. Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071114 Termination date: 20200113 |
|
CF01 | Termination of patent right due to non-payment of annual fee |